Lunenfeld-Tanenbaum Research Institute

Bruker Advances CCS-Enabled 4D-Proteomics timsTOF Solutions for Immunopeptidomes and Glycoproteomics at US HUPO

Retrieved on: 
Monday, March 11, 2024
Software, Research, Hardware, Pharmaceutical, Oncology, Technology, Medical Devices, Infectious Diseases, Genetics, Health Technology, Science, Biotechnology, Health, QC, GPU, Utrecht University, Pharmacy, IRT, Drug discovery, Radboud University Nijmegen, Cell biology, Biomarker, Molecular genetics, Bruker, University, Ultra, University of Michigan, Proteomics, Peptide, Infection, Pulse, Neoplasm, Glycomics, Lunenfeld-Tanenbaum Research Institute, TIMS, Multimedia, Medical director, BRKR, Pathology, Medical device

At the 20th US Human Proteome Organization Congress 2024, Bruker Corporation (Nasdaq: BRKR) announced progress in immunopeptidomics, glycoproteomics and other CCS-enabled 4D-proteomics workflows.

Key Points: 
  • At the 20th US Human Proteome Organization Congress 2024, Bruker Corporation (Nasdaq: BRKR) announced progress in immunopeptidomics, glycoproteomics and other CCS-enabled 4D-proteomics workflows.
  • The rapid advances in deep, at-scale proteomics, glycomics and peptidomics research solutions complement other performance-leading life-science tools for the post-genomic era by Bruker.
  • Bruker enhances its timsTOF HT and timsTOF Ultra systems with the new software Novor v2.0 for de novo immunopeptidomic profiling.
  • Our software suite supports the analysis of PASEF data, and we are delighted that Bruker now offers it with timsTOF instruments.

High Sensitivity and Specificity of the Xenium Platform from 10x Genomics Outperforms NanoString's CosMx and Vizgen's Merscope in Benchmarking Preprint

Retrieved on: 
Wednesday, December 13, 2023
Assistant, Associate, University, Breast, Research, Broad Institute, Gene, Biology, Cedars-Sinai Medical Center, Tissue, Genomics, Postdoctoral researcher, Breast cancer, Prostate, Workflow, NanoString Technologies, Spatial analysis, Lunenfeld-Tanenbaum Research Institute, Preprint, Cell, RNA, Medical imaging, Rosenbergia xenium

PLEASANTON, Calif., Dec. 13, 2023 /PRNewswire/ -- 10x Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial biology, announced today that a new non-peer-reviewed study has independently evaluated the technical performance of three spatial imaging platforms and found the Xenium In Situ platform demonstrated higher quality transcript counts per gene at higher specificity for 22 formalin-fixed paraffin-embedded (FFPE) tissues compared to NanoString's CosMx and Vizgen's MERSCOPE. This comparison, presented in a preprint posted to bioRxiv, marks one of the first benchmarking studies of commercially available spatial imaging platforms using data independently generated in the customer's own lab.

Key Points: 
  • Xenium consistently demonstrated higher sensitivity than both CosMx (more than 12x the sensitivity) and MERSCOPE (over 2x more sensitive) when it came to comparing the expression levels of shared genes.
  • Importantly, the Xenium platform accurately measured low-expressing genes unlike CosMx and showed better correlations with healthy tissue than MERSCOPE.
  • In healthy breast samples, Xenium identified all nine expected cell types, but CosMx only resolved six of these cell types.
  • Cell-type identification data for MERSCOPE was only provided for breast cancer tissue and, much like CosMx, MERSCOPE did not recognize all the expected cell types.

Breast Cancer Society of Canada Grants $250,000 To Precision Oncology Research at Dalhousie University

Retrieved on: 
Wednesday, June 15, 2022
Breast cancer, Signal transduction, Department, Reynolds cancer charities, World, Biochemistry, HER2, Harvard Medical School, BCSC, Dalhousie University, CEO, Breast, MIT, Ontario Cancer Institute, Precision medicine, Recurrence, Cancer, Lunenfeld-Tanenbaum Research Institute, Research, Columbia Senior Executive Program, Molecular biology, Faculty, JHSPH Department of Biochemistry and Molecular Biology, Biomarker, Division of Signal Transduction Therapy, Artificial intelligence, World Health Organization, Medical school, Patient, Diagnosis, GLOBE, Division, Pharmaceutical industry, Medical imaging, Medicine

The overarching goal of the research project is to identify new biomarkers that distinguish recurrence potential from HER2+ breast cancer.

Key Points: 
  • The overarching goal of the research project is to identify new biomarkers that distinguish recurrence potential from HER2+ breast cancer.
  • The breast cancer research projects that have been selected for funding will aim to advance screening, detection, precision oncology and patient reported outcomes, enhancing care for Canadians with breast cancer.
  • Kimberly Carson, CEO of the Breast Cancer Society of Canada, said, Dr. Marignanis research will directly impact the lives of breast cancer patients by developing treatment plans that are tailored to the individual.
  • The Breast Cancer Society of Canada (BCSC) is a registered, national, non-profit, charitableorganization dedicated to saving lives through breast cancer research.

Repare Therapeutics Announces Publication of Preclinical Data in Nature Demonstrating the Potential of PKMYT1 Inhibitor RP-6306 in Tumors With CCNE1 Amplification

Retrieved on: 
Wednesday, April 20, 2022
Oncology, Health, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, DNA, Clinical trial, PKMYT1, ISCB Senior Scientist Award, U.S. Securities and Exchange Commission, COVID-19, Security (finance), University, Research, MD, ATR, Private Securities Litigation Reform Act, Genome, Lunenfeld-Tanenbaum Research Institute, Doctor of Philosophy, Risk, Patient, Department, EVP, Mount Sinai Health System, CCNE1, Company, CIHR, Therapy, SEC, Forward-looking statement, Neoplasm, Durocher, FOLFIRI, Safety, Public, Senior, CRISPR, AMF, Canadian Institutes of Health Research, Antibiotics, Pharmaceutical industry, Nature, Neurological reparative therapy

SNIPRx, Repares proprietary, genome-wide, CRISPR-based screening approach, was used to uncover CCNE1 amplification as synthetic lethal to PKMYT1 inhibition.

Key Points: 
  • SNIPRx, Repares proprietary, genome-wide, CRISPR-based screening approach, was used to uncover CCNE1 amplification as synthetic lethal to PKMYT1 inhibition.
  • RP-6306 is a first-in-class and highly selective PKMYT1 inhibitor, and these preclinical data show its ability to target CCNE1-amplfied tumors and profoundly inhibit tumor growth, said Michael Zinda, PhD, EVP and Chief Scientific Officer of Repare.
  • This led to the identification of a previously uncharacterized vulnerability to PKMYT1 inhibition that spurred the development of RP-6306 by Repare Therapeutics."
  • Repare Therapeutics is a leading clinical-stage precision oncology company enabled by its proprietary synthetic lethality approach to the discovery and development of novel therapeutics.

Nikon Opens First Center of Excellence in Canada at Lunenfeld-Tanenbaum Research Institute of Sinai Health in Toronto

Retrieved on: 
Thursday, March 18, 2021
Nikon, Lunenfeld-Tanenbaum Research Institute, Mount Sinai Hospital, Companies, Live-preview digital cameras, Economy of Japan, Industry economics)

Canada's first Nikon Center of Excellence provides access to the latest in imaging technologies to its trainees, visiting scholars, collaborators at the University of Toronto, and the greater Toronto community.

Key Points: 
  • Canada's first Nikon Center of Excellence provides access to the latest in imaging technologies to its trainees, visiting scholars, collaborators at the University of Toronto, and the greater Toronto community.
  • The Center of Excellence is also well positioned to foster meaningful relationships between LTRI's researchers and Nikon's hardware and software development teams.
  • "I am delighted that the LTRI was chosen as the inaugural Nikon Centre of Excellence in Canada," said Laurence Pelletier, Ph.D., Senior Investigator, LTRI and Director of the Nikon Center of Excellence.
  • The Lunenfeld-Tanenbaum Research Institute, located at Mount Sinai Hospital, is one of the leading biomedical research facilities in the world.

First Participants Dosed in Appili Therapeutics’ Phase 2 Clinical Trial Evaluating Favipiravir for COVID-19 Outbreak Control in Canadian Long-Term Care Homes

Retrieved on: 
Tuesday, October 20, 2020
Infectious diseases, Biotechnology, Health, Clinical trials, Chemistry, Physical sciences, Allison McGeer, COVID-19 Immunity Task Force, Ebola, Clinical research, Chemical compounds, Favipiravir, Randomized controlled trial, Lunenfeld-Tanenbaum Research Institute, McGeer

Appili is sponsoring the Phase 2 cluster-randomized placebo-controlled trial (cluster-RCT) evaluating the effectiveness of favipiravir as a preventative measure against COVID-19 outbreaks in long-term care (LTC) facilities.

Key Points: 
  • Appili is sponsoring the Phase 2 cluster-randomized placebo-controlled trial (cluster-RCT) evaluating the effectiveness of favipiravir as a preventative measure against COVID-19 outbreaks in long-term care (LTC) facilities.
  • Dr. Allison McGeer , senior clinician scientist at Sinai Healths Lunenfeld-Tanenbaum Research Institute (LTRI) in Toronto, is the studys primary investigator.
  • The study population will include elderly subjects with co-morbidities and front-line healthcare workers with recent COVID-19 exposure or confirmed infection.
  • Dosing the first cluster of participants in our COVID-19 trial is an important milestone for Appilis program.

Consortium Backs Netherton Syndrome Project From Sinai Health

Retrieved on: 
Tuesday, May 12, 2020
Organ systems, Medicine, RTT, Genodermatoses, Netherton syndrome, Medical specialties, Kallikrein, Lunenfeld-Tanenbaum Research Institute, Dermatitis

The project was initiated in partnership with a group of scientists from Sinai Healths Lunenfeld-Tanenbaum Research Institute (LTRI) in Toronto, Canada and focuses on a specific group of enzymes called tissue kallikreins.

Key Points: 
  • The project was initiated in partnership with a group of scientists from Sinai Healths Lunenfeld-Tanenbaum Research Institute (LTRI) in Toronto, Canada and focuses on a specific group of enzymes called tissue kallikreins.
  • These proteins play a critical role in development of Netherton Syndrome and other skin inflammatory diseases.
  • With $1.75M additional financing from the consortium, the project will now complete crucial pre-clinical studies including lead optimization with the goal of generating a kallikrein-targeting candidate for IND-enabling studies by 2021.
  • According to lead project scientist Dr. Ioannis Prassas at LTRI, the novel kallikrein-focused approach holds promise for treating Netherton Syndrome and, more broadly, atopic inflammatory dermatitis.